The FDA has approved Kerendia® (finerenone) to reduce the risk of cardiovascular death, hospitalization for HF, and urgent HF visits.

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on July 16, 2025 it granted stock options to purchase an ...

Cardiologist explains that a heart attack isn't always fatal, and even patients with a very low survival chance can be saved with timely, advanced cardiac care.

“Weight loss quality is a new concept….The discussion no longer revolves around the lack of adequate efficacy but rather ...

Mirdametinib is marketed under the brand name EZMEKLY ® in the European Union and is conditionally approved by the European Commission (EC) for the treatment of symptomatic, inoperable plexiform ...

There is increased risk for major gastrointestinal bleeding with edoxaban vs VKA therapy in patients with atrial fibrillation following TAVR.

Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced gross revenue from sales ...

Ryoncil ® is the first and only FDA approved mesenchymal stromal cell (MSC) product in the Unites States and became commercially available for purchase on March 28, 2025, within one quarter of ...